Search / Trial NCT00000178

Multicenter Trial of Prednisone in Alzheimer's Disease

Launched by NATIONAL INSTITUTE ON AGING (NIA) · Oct 29, 1999

Apply for Trial

Trial Information

Current as of December 03, 2023

Completed

Keywords

Alzheimer's Disease Prednisone Anti Inflammatory Agents

Description

No description provided

Gender

All

Eligibility criteria

  • Inclusion Criteria:
  • Patients with Alzheimer's disease who are in stable medical condition
  • Exclusion Criteria:
  • Patients with diabetes or severe osteoporosis

Attachments

readout_NCT00000178_2023-12-03.pdf

4.5 MB

NCT00000178_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Baltimore, Maryland, United States

Los Angeles, California, United States

Tampa, Florida, United States

Jacksonville, Florida, United States

Kansas City, Kansas, United States

Minneapolis, Minnesota, United States

St. Louis, Missouri, United States

New York, New York, United States

Pittsburgh, Pennsylvania, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Birmingham, Alabama, United States

Rochester, New York, United States

San Diego, California, United States

New York, New York, United States

White Plains, New York, United States

Indianapolis, Indiana, United States

New York, New York, United States

Miami, Florida, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0